COFEPRIS

Alejandro Svarch Pérez, head of the Federal Commission for the Protection against Sanitary Risks (Cofepris), underscored the critical need for regulatory certainty, transparency, and...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has granted open commercialization approval for Paxlovid (nirmatrelvir/ritonavir), a Pfizer-developed medication used to treat...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has officially approved the sanitary registration of enzalutamide capsules, marking a significant milestone in...

The Mexican market regulator Federal Commission for the Protection against Sanitary Risk, COFEPRIS, has introduced a new draft for the NOM for Medical Device...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has authorized a groundbreaking clinical trial to evaluate the safety, tolerability, and efficacy of...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has announced an update to the list of medical establishments shut down due to...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has approved the sanitary registration of dostarlimab, an innovative biotechnological drug for endometrial cancer...

The Federal Commission for Protection against Health Risks (Cofepris) has authorized the second software for atrial fibrillation (AF) to use as a medical device....

The Federal Commission for Protection against Health Risks (Cofepris) has authorized a groundbreaking clinical trial to evaluate the efficacy, immunogenicity, and safety of a...

The Federal Commission for Protection against Health Risks (Cofepris) has authorized the second software for atrial fibrillation (AF) to use as a medical device....

The Federal Commission for Protection against Health Risks (Cofepris) has announced the authorization of the first high-tech software designed to enhance the precision and...

The Federal Commission for Protection against Sanitary Risks (Cofepris) has announced the emergency use authorization for the Patria COVID-19 vaccine, developed by Laboratorio Avimex...

The Mexican regulator, COFEPRIS, released the 5.0 edition of the Supplement of Medical Devices of the Mexican Pharmacopoeia (Pharmacopoeia), incorporating regulatory requirements for Software...